No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study

Bibliographic Details
Main Authors:	M. Bandini, E. Zaffuto, S. Scuderi, F. Pederzoli, L. Marandino, D. Raggi, F. Barletta, G. Gandaglia, N. Fossati, G. Burgio, M. Moschini, S. Zamboni, L. Afferi, S. Comara, A. Briganti, F. Montorsi, R. Colombo, A. Necchi, A. Gallina
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331323

Internet